The results are in on the Phase I/II trial of the mesothelioma drug ONCOS-102 and researchers say there is reason to be excited. As Surviving Mesothelioma first reported in the fall of 2016, ONCOS-102 and standard chemotherapy significantly slowed the growth of malignant mesothelioma tumors in preclinical studies of infected mice. Now, the first human trial suggests that it can do the same thing in … Continue reading New Immunotherapy Drug Stops Mesothelioma in Half of Patients Tested
Patients with malignant mesothelioma who have not gotten better after chemotherapy are being invited to enroll in a clinical trial of a combination drug that could be the future of mesothelioma treatment. The drug is called SEL-403. Developed by Selecta Biosciences, the drug seeks to get around the problem of the body producing antibodies that decrease the effectiveness of certain mesothelioma drugs. What is SLE-403 … Continue reading Mesothelioma Patients Recruited to Test Promising New Combo Drug
Researchers at Stanford University are about to move into human trials of what some believe may be the most promising treatment yet for malignant mesothelioma and other types of solid tumors. The new treatment is an immunotherapy vaccine that combines two separate agents, both of which are already being tested independently. Unlike some other types of immunotherapy – including drugs like Keytruda and Opdivo … Continue reading A Cure for Mesothelioma? Hopes High for New Cancer Vaccine
Researchers at one of the nation’s top cancer institutes are betting on a combination of radiation and immunotherapy in the continued pursuit of better treatments for malignant mesothelioma. Memorial Sloan Kettering in New York is now recruiting relapsed mesothelioma patients into a safety and efficacy study of stereotactic body radiation therapy (SBRT) and the immunotherapy drug avelumab. The new trial is based on the idea … Continue reading New Mesothelioma Treatment Combines Immunotherapy and Targeted Radiation
A new Japanese study is calling into question the value of a common prognostic test for people with malignant pleural mesothelioma. The test is called the neutrophil-to-lymphocyte ratio or NLR and it is used in many types of diseases, including mesothelioma, as a marker for inflammation. But in a new report published in the journal In Vivo, researchers with the Hyogo Prefectural Amagasaki General Medical … Continue reading Blood Test May Not Predict Mesothelioma Survival as Well as Hoped
A new stem cell vaccine that has proven effective against malignant mesothelioma and several other cancers in mice might offer a promising new way to treat the asbestos cancer. Although rare, malignant mesothelioma is one of the most treatment-resistant malignancies. Even with aggressive therapies, most people diagnosed with mesothelioma do not survive longer than about 18 months. But research conducted at Stanford University and published in … Continue reading Could Stem Cell Vaccine Lead to Mesothelioma Cure?
A new study is casting some doubt on the value of a protein called PD-L1 as a way to select mesothelioma patients for targeted immunotherapy. Several of the most promising new treatments for malignant mesothelioma, including pembrolizumab (Keytruda) and avelumab (Avastin), are designed to inhibit PD-L1, a protein cells used to evade detection by the immune system. PD-L1 inhibitors like Keytruda have become an important … Continue reading Study Highlights Challenge of Selecting Patients for Mesothelioma Immunotherapy
Immunotherapy is emerging as one of the most promising new treatment approaches for a wide range of cancers, including malignant pleural mesothelioma, the treatment-resistant lung-related cancer caused by asbestos exposure. Every year, more than 2,500 Americans are diagnosed with pleural mesothelioma. Most will die of the illness within 18 months, even with the most advanced chemotherapeutic, radiotherapeutic, and surgical treatments. But immunotherapy, which recruits the … Continue reading Immunotherapy for Mesothelioma: Who Are the Best Candidates?
France has a new standard of care for people with unresectable malignant pleural mesothelioma. Along with the chemotherapy drugs cisplatin and pemetrexed (Alimta), French doctors are now regularly also using bevacizumab (Avastin) to boost the effectiveness of mesothelioma chemotherapy. The addition of Avastin to standard mesothelioma care came after the 2016 French-led mesothelioma avastin cisplatin pemetrexed study (MAPS) showed that the VEGF inhibitor improved mesothelioma … Continue reading Three-Drug Combo is New Standard of Care for Pleural Mesothelioma in France
The ratio of neutrophils to lymphocytes – a way of measuring inflammation in the body of people with malignant pleural mesothelioma – may help doctors predict how well they will respond to treatment. That is the conclusion of mesothelioma researchers at China’s Sichuan University. In a new article in the journal Oncotarget, the team observed that NLR has been associated with survival in other types … Continue reading Inflammation Marker May Predict Mesothelioma Prognosis